All Search Results
News Releases
Apr 07, 2026, 15:43 ET LBB Specialties and DMC Biotechnologies Partner to Bring Fermented Inositols to the U.S. Market
Biotechnologies is a U.S.-based biomanufacturer redefining how the world produces specialty chemicals and ingredients. Through precision fermentation and synthetic biology, DMC creates sustainable, bio-based alternatives that reduce carbon emissions, enhance quality, and improve global supply chain resilience. The
More news about: LBB Specialties LLC
Apr 07, 2026, 15:16 ET LBB Specialties and DMC Biotechnologies Partner to Bring Fermented Inositols to the U.S. Market
Biotechnologies is a U.S.-based biomanufacturer redefining how the world produces specialty chemicals and ingredients. Through precision fermentation and synthetic biology, DMC creates sustainable, bio-based alternatives that reduce carbon emissions, enhance quality, and improve global supply chain resilience. The
More news about: LBB Specialties LLC
Apr 02, 2026, 12:00 ET Andrew Maynard, Renowned Futurist, AI Expert, and Director of ASU Future of Being Human Initiative, to Join Ellucian Live 2026 Mainstage
governance, he has become a leading voice helping institutions and society navigate the promises and risks of transformative technologies — from AI and synthetic biology to nanotechnology.As artificial intelligence rapidly evolves from emerging trend to embedded reality, leaders across higher education are
More news about: Ellucian
Apr 01, 2026, 15:59 ET Synthego Welcomes Supreme Court Order Finalizing Invalidation of Agilent CRISPR Patents
CRISPR-enabled research and therapeutics can flourish.About SynthegoSynthego is a pioneering biotechnology company specializing in synthetic biology and genome engineering. Dedicated to providing scientists with the tools, expertise, and support needed to accelerate scientific discovery, Synthego's
More news about: Synthego
Mar 31, 2026, 09:07 ET 2026 CANADA GAIRDNER AWARDS RECOGNIZE WORLD-LEADING SCIENTISTS FOR BREAKTHROUGH DISCOVERIES ADVANCING HUMAN HEALTH
development of treatments that can target harmful bacteria while preserving beneficial microbes, and they are informing genome-editing technologies and synthetic biology applications. By mapping the strategies of both bacteria and phages, Dr. Maxwell's research is opening new paths for fighting infections, managing
More news about: Gairdner Foundation
